Neuren Pharmaceuticals Updates Share Buy-Back Progress

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an announcement.

Neuren Pharmaceuticals Limited has announced an update on its ongoing share buy-back program, with a total of 3,597,980 securities bought back before the previous day and an additional 37,159 securities acquired on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value, reflecting a proactive approach to optimizing financial operations.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is primarily engaged in creating treatments for conditions such as Rett syndrome and Fragile X syndrome, aiming to address unmet medical needs in these areas.

Average Trading Volume: 767,494

Technical Sentiment Signal: Buy

Current Market Cap: A$1.79B

See more insights into NEU stock on TipRanks’ Stock Analysis page.